Novo Nordisk’s CagriSema Falls Short Against Lilly’s Retatrutide as Potent Efficacy Redefines Market Battle
In the escalating race for dominance in the multi-billion dollar obesity drug market, Novo Nordisk has unveiled new data for its next-generation candidate CagriSema. However, the results are already being overshadowed by competing data from Eli Lilly, which is demonstrating what analysts call “super high weight loss” that resets the bar for the entire industry .
Novo Nordisk announced headline results from the Phase III REIMAGINE 2 trial on February 2, revealing that its once-weekly combination drug CagriSema achieved a superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes at 68 weeks . While this outperformed Novo’s own blockbuster Wegovy (which showed 10.2% weight loss), it fell significantly short of the lofty 25% weight loss target the company had previously set for the drug candidate .
Latest News————>   Mens Large Hill Ski Jumping Results – 2026 Winter Olympics
The timing of the data release proved problematic for the Danish pharmaceutical giant. Just weeks prior, Eli Lilly’s experimental triple agonist retatrutide delivered the best weight loss ever recorded in a clinical study. In a Phase III trial involving patients with obesity and knee osteoarthritis, retatrutide helped patients lose up to 28.7% of their body weight—a figure analysts at Evercore ISI suggest places Lilly’s drug in a new “super high weight loss” category .
The divergent fortunes of the two companies extend beyond clinical data. Novo Nordisk recently warned investors that it expects a sales decline of 5% to 13% in 2026 due to U.S. pricing pressure and patent expirations. In contrast, Eli Lilly has forecast sales to grow by 25% this year, bolstered by the superior efficacy of its portfolio .
Leerink Partners analyst David Risinger emphasized that the contrast in data and outlook “firmly convinced investors that Lilly is positioned to be the dominant force in obesity treatment moving forward.” While Novo has submitted CagriSema for FDA approval and awaits a green light later this year, the company is also running a head-to-head study of CagriSema against Lilly’s tirzepatide, with results expected imminently .
Source Link:
Leave a comment